

SUPPLEMENTARY MATERIAL

Table 1(suppl): Comparisons between valid cases and excluded ones, for the model's variables

Predictor	Total	Cases excluded	Cases valid	Valor p
• Age	49.1±13.8	49.0±15.8	49.1±13.4	0.568
• Charlson Index	2.56±1.89	2.79±2.00	2.50±1.86	0.013
• Organ damage (SLICC/ACR DI)	1.42±1.82	1.41±1.91	1.42±1.79	0,643
• Katz Severity Index	4.41±1,97	4.42±2.03	4.41±1.96	0.781
• Chronic Kidney Disease	167 (10.3%)	19 (8.4%)	148 (10.6%)	0.312
• Previous hospitalization	416 (25.6%)	62 (27.2%)	354 (25.4%)	0.564
• Previous serious infection	99 (5.5%)	11 (3.1%)	88 (6.1%)	0.027
• Prednisone (maximum doses)				
- ≤5 mg		-	526 (68.2%)	
- >5 mg and <10 mg		-	116 (15.0%)	
- ≥10 mg and <30 mg		-	100 (13.0%)	
- ≥30 mg		-	29 (3.8%)	
• Antimalarials	451 (24.8%)	72 (19.9%)	379 (26.0%)	0.017
• Cyclophosphamide	15 (0.8%)	3 (0.8%)	12 (0.8%)	1.000
• Mycophenolate	131 (7.2%)	17 (4.7%)	114 (7.8%)	0.041

Table 2 (suppl): Model building and correction for overadjustment			
Potential predictors	OR (95%CI) [p value]	Coefficient (ln(OR))	Adjusted coefficient
Sociodemographics			
• Age			
- <60 years	Reference	Reference	Reference
- ≥60 years	6.06 (1.91-19.3) [0.002]	1.80	1.30
Clinical features			
• Charlson comorbidity index			
• Chronic kidney disease			
• Damage (SLICC/ACR DI)			
• Severity (Katz Index)			
• Hospitalization due to SLE	6.84 (1.68-27.8) [0.007]	1.92	1.39
• Previous severe infection	6.09 (1.94-19.1) [0.002]	1.81	1.31
Treatment			
• Prednisone: (max. dosage)			
- ≤5 mg	Reference	Reference	Reference
- >5 mg and <10 mg	2.07 (0.49-8.73) [0.323]	0.73	0.53
- ≥10 mg and <30 mg	2.29 (0.51-10.3) [0.280]	0.83	0.60
- ≥30 mg	8.93 (1.69-47.1) [0.010]	2.19	1.58
• Antimalarials			
• Cyclophosphamide			
• Mycophenolate			
Constant	0.0017	-6.37	-5.40
Performance of the model			
% right classification	97.8%		
Discrimination			
• AUC	0.874 (0.774-0.974)		0.810
• C-Statistic			(0.715-0.893)
Calibration			
• Goodness-of-fit (Hosmer-Lemeshow)	p=0.932		
SLICC/ACR DI: SLICC/ACR Damage Index; SLE: systemic lupus erythematosus; max: maximum. AUC: area under the curve.			

Table 3 (suppl): Predictor reliability	
Predictors	Number of times selected * N (%)
Age (years) ≥ 60	92 (92%)
Previous SLE-related hospitalization	67 (67%)
Previous serious infection	87 (87%)
GC dose (prednisone or equivalent)	
>5 mg and <10 mg	24 (24%)
≥ 10 mg and <30 mg	29 (29%)
≥ 30 mg	80 (80%)
Charlson comorbidity index	27 (27%)
Chronic kidney disease	17 (17%)
Damage (SDI)	29 (29%)
Severity (KSI)	57 (57%)
Antimalarials	15 (15%)
Cyclophosphamide	11 (11%)
Mycophenolate	32 (32%)
*Number of times selected in bootstrapping procedure/100 samples. SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index; KSI: Katz Severity Index.	

Table 4 (suppl): Transformation of the coefficients and OR of the adjusted model

Transformation	Mathematical formulation
<i>Coefficient-based</i>	
Transformation 1	Eliminates the constant and multiplies the coefficient by 5 to increase the range of the scale
Transformation 2	Sum 1 to transformation 1 (avoiding the 0 value in reference categories)
Transformation 3	Eliminates the constant and divides by the lowest coefficient
Transformation 4	Sum 1 to transformation 3 (avoiding the 0 value in reference categories)
Transformation 5	Eliminates the constant and divides by the lowest coefficient and multiplies by 2
Transformation 6	Sum 1 to transformation 5 (avoiding the 0 value in reference categories)
<i>OR-based</i>	
Transformation 7	Divide OR by the lowest OR and round off the value
Transformation 8	Sum 1 to transformation 7 (avoiding the 0 value in reference categories)
Transformation 9	OR rounded
Transformation 10	Sum 1 to transformation 7 (avoiding the 0 value in reference categories)
Transformation 11	OR rounded with 0 in no significant categories of GC
OR: odds ratio. GC: Glucocorticoids	

Table 5 (suppl): Transformations based on the coefficients of the adjusted model

Predictors	β adjusted	Transformations					
		1	2	3	4	5	6
• Age							
- <60 years	0	0	1	0	1	0	1
- ≥60 years	1.30	7	8	2	3	4	5
• Hospitalization due to SLE	1.39	7	8	3	4	6	7
• Previous infection	1.31	7	8	2	3	4	5
• Prednisone (max. dosage)	0	0	1	0	1	0	1
- ≤5 mg	0.53	3	4	1	2	2	3
- >5 mg y <10 mg	0.60	3	4	1	2	2	3
- ≥10 mg y <30 mg	1.58	8	9	3	4	6	7
- ≥30 mg							
• Constant	-5.40						
Scale range		0-29	0-33	0-10	0-14	0-20	0-24

SLE: Systemic lupus erythematosus. max: maximum.

Table 6 (suppl): Transformations based on the ORs of the adjusted model

Predictors	OR	Transformations				
		7	8	9	10	11
• Age						
- <60 years	Ref	0	1	0	1	0
- ≥60 years	3.67	2	3	4	5	4
• Hospitalization due to SLE	4.01	2	3	4	5	4
• Previous infection	3.71	2	3	4	5	4
• Prednisone (max. dosage)	Ref	0	1	0	1	0
- ≤5 mg	1.70	1	2	2	3	0
- >5 mg and <10 mg	1.82	1	2	2	3	0
- ≥10 mg and <30 mg	4.85	3	4	5	6	5
- ≥30 mg						
• Constant	0.00					
Scale range		0-9	0-13	0-17	0-21	0-17

max: maximum.

Figure 1 (suppl): ROC curves for the transformations of the OR and coefficients